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Abstract
Few data exist on risk factors (RF) for surgical site infections (SSI) among patients treated in an enhanced recovery after surgery
(ERAS) pathway. This study aimed to assess RF for SSI after pancreas surgery in a non-ERAS group and an ERAS cohort.
An exploratory retrospective analysis of all pancreas surgeries prospectively collected (01/2000–12/2015) was performed. RF for
SSI were calculated using uni- and multivariable binary logistic regressions in non-ERAS and ERAS patients.
Pancreas surgery was performed in 549 patients. Among them, 144 presented a SSI (26%). In the non-ERAS group (n=377), SSI
incidence was 27% (99/377), and RF for SSI were male gender and preoperative biliary stenting. Since 2012, 172 consecutive
patients were managed within an ERAS pathway. Forty-five patients (26%) had SSI. On multivariable analysis no RF for SSI in the
ERAS cohort was found. In the ERAS group, patients with a pathway compliance70% had higher occurrence of SSI (30/45=67%
vs. 7/127=6%, p<0.001) and patients with and without SSI had similar median overall compliances (77%, IQR 71–80 vs. 80%, IQR
73–83, p=0.097).
In the non-ERAS cohort, male gender and preoperative biliary stenting were RF for SSI, whereas in the ERAS group no RF for SSI
was found. In an ERAS pathway, having an overall compliance >70% might diminish the SSI rate.
Abbreviations: ASA = American Society of Anesthesiologists, CDC = Centers for Disease Control and Prevention, DGE =
delayed gastric emptying, ECOG = Eastern Cooperative Oncology Group, ERAS = enhanced recovery after surgery, ICU = intensive
care unit, ISGPS = International Study Group for Pancreas Surgery, LoS = length of stay, NRS = nutritional risk screening, POPF =
postoperative pancreatic fistula, SSI = surgical site infections.
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infection[4]1. Introduction
Pancreas surgery induces a substantial number of postoperative
complications, ranging from 40% to 70%.[1–3] In particular,
septic complications are common (around 35%).[4] Different risk
factors for septic complications after pancreas surgery are
known, such as age >70 years, prolonged operative time,
intraoperative blood transfusion, total parenteral nutrition, bile
contamination, high body-mass index, and open surgery.[4–6]
Wound infections and intra-abdominal abscesses subsumed as
surgical site infections (SSI) represent the most common septicEditor: Giuseppe Malleo.
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complication after pancreas surgery. Malnutrition, small main
pancreatic duct, biliary stenting, or operative time have been
found to increase the risk for SSI after pancreatectomy.[7–9]
Recently,enhancedrecoveryaftersurgery(ERAS)protocolshave
been implemented in pancreas surgerywith favorable results.[10,11]
This new perioperative management reduces the surgical stress
response by maintaining the physiological homeostasis and
diminishes in certain reports postoperative complications.[12] So
far, only scarce data exist concerning the occurrence of SSI after
pancreas surgery in patients treated within ERAS protocols.
The aim of this study was to define risk factors for SSI after
pancreas surgery in patients treatedwithin an ERAS pathway and
in patients with non-ERAS management.
2. Methods
2.1. Patients and data collection
All consecutive patients who underwent surgery of the pancreas
at the Department of visceral surgery (Lausanne University
Hospital CHUV, Lausanne, Switzerland) were included. An
exploratory retrospective analysis was performed. Patients’ data
were collected from our prospectively maintained institutional
database from January 2000 to December 2015. All types of
pancreas operations for various etiologies were included.
Complications occurring during hospitalization or within the
first 30 postoperative days were graded according to the Clavien
classification.[13] Minor complications were defined as grade I to
II, whereas major complications as grade III to IV.[13] Grade V
defined the mortality rate.[13] Definitions from the International
Joliat et al. Medicine (2018) 97:31 MedicineStudy Group for Pancreas Surgery (ISGPS) were used for
postoperative pancreatic fistula (POPF), delayed gastric emptying
(DGE), and hemorrhage.[14–16] SSI was defined according to the
Centers for Disease Control and Prevention (CDC).[17] Superfi-
cial (skin and subcutaneous) and deep (fascia and muscle layer)
incisional SSI was defined as an infection occurring within 30
days after surgery or during hospitalization with at least one of
the following: purulent drainage from the incision, wound
dehiscence, and fever or local pain, wound abscess seen on
anatomical, histological, or imaging.[17] Organ/space SSI was
defined as infection occurring within 30 days after surgery or
during hospitalization and involving a body part deeper than the
fascial/muscle layer that was opened or manipulated during the
surgical procedure with at least one of the following: purulent
drainage from a drain located in an organ/space, microbiological
identification of organisms, abscess involving the organ/space
seen on anatomical, histological or imaging.[17] Non-pancreatic
fistulas (biliary and enteric postoperative fistulas) were classified
into organ/space SSI.
The preoperative general state of a patient was measured
according to the American Society of Anesthesiologists (ASA)
score[18] and the Eastern Cooperative Oncology Group (ECOG)
performance status.[19] Length of stay (LoS) was calculated from
operation day until discharge day or patient’s in-hospital death.
Active smoking was defined preoperatively by direct question to
the patients.Table 1







67 (57–74) 65 (54–74) .301‡
Men 83 (48%) 226 (60%) .012
BMI, kg/m2
∗
24 (22–27) 24 (21–27) .474
Active smokers 54 (31%) 160 (42%) .014
Preoperative jaundice 60 (35%) 158 (42%) .076
Preoperative biliary stenting 53 (31%) 138 (37%) .209
ECOG status ≥2 6 (4%) 37 (10%) .009
ASA score .184
1/2 9 (5%)/111 (65%) 26 (7%)/244 (65%)
3/4 52 (30%)/0 99 (26%)/8 (2%)2.2. ERAS group
ERASwas implemented inOctober 2012 for all pancreas patients
without exclusion.[10] The institutional ERAS protocol is based
on the guidelines of the ERAS Society.[11] In particular, for
patients with tumors of the pancreatic head and preoperative
jaundice, biliary stenting was performed only if the serum
bilirubin concentration was >250mmol/L, in case of cholangitis,
delayed surgery and/or if a neoadjuvant treatment was intended.
Early postoperative mobilization (out of bed on operation day,
walking on postoperative day 1) and oral intake (from
postoperative day 1) were encouraged. In the ERAS group, the
P-POSSUM score[20] was calculated and the Nutritional Risk
Screening (NRS)[21] was used to establish the nutritional state of
patients preoperatively. The mean general ERAS compliance was
defined as the mean of the sum of all fulfilled ERAS items divided
by all ERAS items per patient. In the ERAS cohort, comparison of
SSI incidences was performed in patients with median overall
compliance 70% and >70% (threshold based on our previous
report of compliance in ERAS pancreas).[10] Uni- and multivari-
able analyses of risk factors for SSI were performed including the
same variables as in the non-ERAS group. Potential risk factors in
both groups included patient demographics, patient character-
istics, intraoperative details, intensive care unit (ICU) stay,
malignant etiology, and POPF based on previous literature and
possible association with SSI.Diabetes 20 (12%) 75 (20%) .021
Hypertension 51 (30%) 129 (34%) .327
Hypercholesterolemia 26 (15%) 65 (17%) .621
Neoadjuvant treatment 7 (4%) 5 (1%) .060
Values are numbers plus percentages in parentheses unless indicated otherwise.
∗
Values are medians (interquartile range).
†x2 test, except.
‡Mann–Whitney U test. Significant P-values appear in bold.
ASA=American Society of Anesthesiologists, BMI=body mass index, ECOG=Eastern Cooperative
Oncology Group, ERAS= enhanced recovery after surgery.2.3. Statistical analysis
For continuous variables, aMann-WhitneyU test or student t test
was used depending on the normality of the distribution and
homogeneity of the variances. Uni- and multivariable analyses
were performed using binary logistic regressions. Multivariable
analysis was performed on items that showed a P< .1 in
univariable binary logistic regression analysis. All statistical
analyses were performed using GraphPad Prism 5.0 (GraphPad2
Software Inc., San Diego, CA) for Mac OS X and SPSS 22 for
Mac OS X (IBM, Armonk, NY). This study was approved by the
local ethics committee and respects the Declaration of Helsinki.3. Results
3.1. Included patients
There were 549 patients who underwent pancreatic surgery
during the study period. Among these patients, 144 (26%)
presented a SSI. Incisional SSI (wound infections) were observed
in 70 patients and organ/space SSI (intra-abdominal abscess) in
50 patients. Twenty-four patients had a concomitant incisional
and organ/space SSI.
Among the 549 patients, 172 followed an ERAS pathway, and
377 had standard pre-ERAS care (non-ERAS group). Character-
istics of the patients are presented in Table 1. There were more
men in the non-ERAS group compared to the ERAS group (60%
vs 48%, P=0.012). Active smokers, diabetic patients, and ECOG
status ≥2 were also more frequent in the non-ERAS group.
Otherwise, all other parameters were similar between both
groups.3.2. Perioperative outcomes (ERAS vs non-ERAS)
The perioperative outcomes of ERAS and non-ERAS patients are
summarized in Table 2. There were more laparotomies (95% vs
85%, P< .001) in the non-ERAS group, and more patients in the
non-ERAS group needed a stay in the ICU (36% vs 19%,
P< .001). Postoperative complications and LoS were similar
between the 2 groups. Of note, postoperative pulmonary and
cardiac complications were similar in the non-ERAS and ERAS
groups, respectively (60/377 vs 24/172, p=0.554 and 21/377 vs
11/172, P= .702). In the non-ERAS group, 99 patients (27%) had
a SSI (50 incisional SSI, 30organ/space SSI, and 19 both
incisional and organ/space SSI). In the ERAS group, 45 patients
(26%) presented a SSI (20 incisional SSI, 20organ/space SSI, and
5 both incisional and organ/space SSI). In the entire cohort, the
only independent risk factor for SSI was preoperative biliary
Table 2





Laparotomy/laparoscopy 147 (85%)/25 (15%) 358 (95%)/19 (5%) <.001







304 (255–353) 315 (240–394) .201x
Pancreatic anastomosis† 118 (69%) 261 (69%) .921
Vascular resection 26 (15%) 57 (15%) 1
Blood loss, mL
∗
400 (200–713) 400 (200–875) .262x
Intensive care unit stay 33 (19%) 134 (36%) <.001
Diagnosis .155
Malignant 115 (67%) 227 (60%)
Benign 57 (33%) 150 (40%)
Length of stay, d
∗
14 (10–24) 16 (11–26) .197x
Surgical site infections 45 (26%) 99 (27%) 1
Morbidity rate 113 (66%) 227 (60%) .256
Clavien I–II 44 (26%) 114 (30%)
Clavien III–IV 69 (40%) 113 (30%)
Mortality (Clavien V) 5 (3%) 15 (4%) .630
Reoperation 30 (17%) 63 (17%) .832
Values are numbers plus percentages in parentheses unless indicated otherwise.
∗
Values are median (interquartile range). DP; others included total pancreatectomy, central
pancreatectomy, Beger operation, or enucleation.
† Pancreaticogastric or pancreaticojejunal anastomosis after Whipple and Beger operations.
‡x2 test except.
xMann–Whitney U test. Significant P-values appear in bold.
DP=distal pancreatectomy, ERAS= enhanced recovery after surgery.
Table 4
Postoperative complications in the non-ERAS cohort (n=377)






Complication rate 143 (51%) 99 (100%) NA
Minor complication 70 (25%) 42 (42%) .001
Major complication 58 (21%) 43 (43%) .001
Mortality 15 (5%) 14 (14%) .005
Reoperation 30 (11%) 33 (33%) <.001
POPF 40 (14%) 29 (29%) <.001
Grade A 8 (3%) 15 (15%)
Grade B 20 (7%) 9 (9%)
Grade C 12 (4%) 5 (5%)
DGE 47 (17%) 26 (26%) .043
Grade A 14 (5%) 6 (6%)
Grade B 24 (9%) 11 (11%)
Grade C 9 (3%) 9 (9%)
Hemorrhage 45 (16%) 39 (39%) <.001
Grade A 24 (9%) 2 (2%)
Grade B 4 (1%) 18 (18%)
Grade C 17 (6%) 19 (19%)
Values are numbers plus percentages in parentheses unless indicated otherwise. POPF, postoperative
pancreatic fistula.
∗
x2 test. Significant P-values appear in bold.
DGE=delayed gastric emptying, ERAS= enhanced recovery after surgery, NA=not applicable,
POPF=postoperative pancreatic fistula, SSI = surgical site infections
Joliat et al. Medicine (2018) 97:31 www.md-journal.comstenting (multivariate analysis, hazard ratio, HR: 1.9 [1.4–2.3],
P= .031).3.3. Complications and length of stay associated with SSI
The overall morbidity rate, that is, minor and major
complications, was 66% for the entire cohort (ERAS andTable 3
Postoperative complications in the entire cohort (ERAS and non-






Complication rate 216 (53%) 144 (100%) NA
Minor complication 105 (26%) 54 (38%) .007
Major complication 94 (23%) 87 (60%) <.001
Mortality 17 (4%) 3 (2%) .308
Reoperation 46 (11%) 47 (33%) <.001
POPF 63 (16%) 46 (32%) <.001
Grade A 29 (8%) 25 (17%)
Grade B 21 (5%) 16 (12%)
Grade C 13 (3%) 5 (3%)
DGE 71 (18%) 48 (33%) <.001
Grade A 29 (7%) 12 (8%)
Grade B 24 (6%) 14 (10%)
Grade C 18 (5%) 22 (15%)
Hemorrhage 63 (16%) 50 (35%) <.001
Grade A 30 (7%) 22 (15%)
Grade B 25 (6%) 25 (17%)
Grade C 5 (3%) 3 (3%)
Values are numbers plus percentages in parentheses unless indicated otherwise.
∗
x2 test. Significant P-values appear in bold.
DGE=delayed gastric emptying, ERAS= enhanced recovery after surgery, NA=not applicable,
POPF=postoperative pancreatic fistula, SSI = surgical site infections.
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non-ERAS). The mortality rate (gradeV) was 3.6%. There were
more minor and major complications in the SSI group
compared to the group without SSI (38% vs 26%, P= .007
and 60% vs 23%, P< .001), whereas the mortality rate was
similar in both groups. The SSI group had higher rates of
reoperations, POPF, DGE, and hemorrhages. Table 3 summa-
rizes the postoperative complications in patients with and
without SSI. Median LoS was longer in case of SSI (25 vs 13
days, P< .001).
In the non-ERAS cohort (n=377), postoperative
complications in patients with and without SSI are shown
in Table 4. SSI was associated with higher minor and major
complications, mortality, reoperations, POPF, DGE, and
hemorrhages.
In the ERAS cohort (n=172), postoperative complications in
patients with and without SSI are summarized in Table 5. SSI
patients had more major complications, reoperations, POPF,
DGE, and hemorrhages.
3.4. Uni- and multivariable analyses of risk factors for SSI
in the non-ERAS group
In the non-ERAS group, male gender and preoperative biliary
stenting were significant risk factors for SSI on multivariable
analysis. Results of the uni- and multivariable analyses are shown
in Table 6.3.5. Uni- and multivariable analyses of risk factors for SSI
in the ERAS group
Two elements were significant on univariable analysis: preoper-
ative biliary stenting and pancreatic anastomosis (pancreatico-
gastric or pancreaticojejunal anastomoses). On multivariable
analysis, no element was significant for risk factor for SSI. The
detailed results are summarized in Table 7.
Table 5
Postoperative complications in the ERAS cohort (n=172) among






Complication rate 77 (61%) 45 (100%) NA
Minor complication 35 (28%) 11 (24%) .804
Major complication 40 (31%) 31 (69%) <.001
Mortality 2 (2%) 3 (7%) .064
Reoperation 16 (13%) 19 (42%) <.001
POPF 27 (21%) 22 (49%) <.001
Grade A 17 (14%) 12 (27%)
Grade B 6 (4%) 5 (11%)
Grade C 4 (3%) 5 (11%)
DGE 28 (22%) 26 (58%) <.001
Grade A 17 (14%) 7 (16%)
Grade B 3 (2%) 4 (9%)
Grade C 8 (6%) 15 (33%)
Hemorrhage 22 (17%) 14 (31%) .028
Grade A 9 (7%) 3 (7%)
Grade B 8 (6%) 7 (16%)
Grade C 5 (4%) 4 (8%)
Values are numbers plus percentages in parentheses unless indicated otherwise.
∗
x2 test. Significant P-values appear in bold.
DGE=delayed gastric emptying, ERAS= enhanced recovery after surgery, NA=not applicable,
POPF=postoperative pancreatic fistula, SSI = surgical site infections
Table 7
Uni- andmultivariable binary logistic regressions for risk factor for
surgical site infection in the ERAS cohort (n=172).
Univariable HR P† Multivariable HR P†
Age, >70 y 1.1 (0.5–2.3) .840
Gender (men) 0.7 (0.4–1.5) .380
BMI, >25 kg/m2 0.7 (0.3–1.4) .294
Active smokers 2.2 (1.0–5.1) .057 1.1 (0.4–3.2) .884
Preoperative jaundice 2.1 (1.0–4.5) .053 1.3 (0.4–4.5) .650
Preoperative biliary stenting 2.2 (1.0–4.7) .041 1.8 (0.5–5.8) .360
ECOG status ≥2 4.3 (0.7–27.7) .115
ASA score >2 0.5 (0.2–1.1) .075 0.8 (0.3–2.0) .627
Diabetes 0.6 (0.2–1.5) .270
Hypertension 0.7 (0.3–1.6) .448
Hypercholesterolemia 0.9 (0.4–2.4) .883
Laparotomy 4.7 (0.6–37) .141
Operative time, >300 min 0.6 (0.3–1.2) .143
Pancreatic anastomosis
∗
17.9 (2.4–134.8) .005 1.6 (0.5–3.4) .124
Vascular resection 1.2 (0.4–3.1) .753
Blood loss, >500 mL 0.6 (0.3–1.4) .272
Intensive care unit stay 0.8 (0.3–1.8) .516
POPF 2.1 (0.6–4.2) .216
Malignancy 0.9 (0.4–2.0) .833
Values are hazard ratios plus 95% confidence intervals in parentheses.
∗
Pancreaticogastric or pancreaticojejunal anastomosis after Whipple and Beger operations.
† Binary logistic regression. Significant P-values appear in bold.
ASA=American Society of Anesthesiologists, BMI=body-mass index, ECOG=Eastern Cooperative
Oncology Group, HR=hazard ratio, POPF=postoperative pancreatic fistula.
Joliat et al. Medicine (2018) 97:31 Medicine3.6. Compliance and SSI in the ERAS group
Median overall compliance to the ERAS protocol was 80%
(interquartile range, IQR: 73–83) in the ERAS group. In addition,
median overall compliances to the ERAS pathway were similar
between patients with SSI and without SSI (77%, IQR: 71–80 vs
80%, IQR: 73–83, P= .097). A compliance to the ERASTable 6
Uni- andmultivariable binary logistic regressions for risk factor for
surgical site infection after pancreatectomy in the non-ERAS
cohort (n=377).
Univariable HR P† Multivariable HR P†
Age, >70 y 1.2 (0.7–1.9) .553
Gender (men) 1.8 (1.1–3.0) .014 2.2 (1.1–4.5) 0.035
BMI, >25 kg/m2 0.8 (0.5–1.3) .311
Active smokers 1.0 (0.6–1.6) .879
Preoperative jaundice 0.7 (0.5–1.2) .201
Preoperative biliary stenting 1.9 (1.2–3.0) .009 2.5 (1.2–5.4) 0.018
ECOG status ≥2 2.0 (0.9–4.5) .107
ASA score >2 1.0 (0.6–1.7) .940
Diabetes 0.9 (0.5–1.6) .819
Hypertension 0.8 (0.5–1.3) .303
Hypercholesterolemia 1.1 (0.6–2.1) .680
Laparotomy 6.8 (0.9–51.6) .065 2.5 (0.2–26.2) 0.443
Operative time, >300 min 2.2 (1.2–4.0) .011 1.4 (0.6–3.4) 0.437
Pancreatic anastomosis
∗
2.0 (1.2–3.6) .013 0.9 (0.3–2.4) 0.849
Vascular resection 2.0 (1.1–3.6) .021 1.3 (0.6–2.9) 0.533
Blood loss, >500 mL 1.8 (1.1–2.9) .028 1.4 (0.7–2.9) 0.371
Intensive care unit stay 0.7 (0.4–1.1) .119
POPF 1.5 (0.8–3.2) .184
Malignancy 0.9 (0.6–1.4) .636
Values are hazard ratios plus 95% confidence intervals in parentheses.
∗
Pancreaticogastric or pancreaticojejunal anastomosis after Whipple and Beger operations.
† Binary logistic regression. Significant P-values appear in bold.
ASA=American Society of Anesthesiologists, BMI=body-mass index, ECOG=Eastern Cooperative
Oncology Group, HR=hazard ratio, POPF=postoperative pancreatic fistula.
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protocol<70% in the ERAS group was associated with higher
occurrence of SSI (30/45=67% vs 7/127=6%, P< .001).3.7. Immunonutrition and postoperative oral supplement
nutrition
In the ERAS group, 101 out of 172 patients (59%) received
preoperative immunonutrition. On postoperative day (POD) 1,
62/172 patients (36%) had oral supplement nutrition. On POD 2
and POD 3, 58/172 patients (34%) and 69/172 patients (40%)
received oral supplement nutrition, respectively.4. Discussion
In this series, the overall incidence of SSI following pancreatic
surgery was 26%, and of note, there was no difference between
non-ERAS (27%) and ERAS patients (26%). Preoperative biliary
stenting and male gender were significant risk factors for SSI in
the non-ERAS group, whereas in the ERAS group no significant
risk factor was found on multivariable analysis. A lower ERAS
pathway compliance rate was found to be associated with a
higher SSI rate.
Both, preoperative biliary obstruction and its endoscopic
treatment by stent insertion carry an increased infectious
risk.[7,22,23] It has been shown that endoscopic biliary inter-
ventions increase the risk for postoperative complications, in
particular cholangitis and POPF.[24,25] Therefore, preoperative
biliary stenting should only be performed in selected patients,
such as jaundiced patients necessitating neoadjuvant chemother-
apy or when biliary sepsis precludes the operation.[7] The ERAS
guidelines for pancreaticoduodenectomy recommend a preoper-
ative biliary drainage only in patients with serum bilirubin
concentrations>250mmol/L.[11] Gavazzi et al[7] suggested that in
preoperatively stented patients antibiotic prophylaxis before
incision with anti-enterococcal activity should be used, whereas
[26]
Joliat et al. Medicine (2018) 97:31 www.md-journal.comSudo et al recommended to perform bile cultures to adjust the
antibiotic prophylaxis according to the culture results in patients
who had preoperative biliary drainage. Male gender has also
been described as a risk factor for infectious complications after
pancreaticoduodenectomy by Okano et al.[4] The exact mecha-
nism is not known but men might react differently to the stress
induced by surgery. Surgical stress response is indeed influenced
by a quantity of variables. The operative duration, a tumoral
inflammatory state with the presence of inflammatory cytokines,
as well as the nutritional status, and the use of laparoscopy play
a role.[27]
This study also showed that the risk factors for SSI after
pancreas surgery were different in the ERAS and non-ERAS
groups. Comparing the same items in the ERAS and non-ERAS
cohorts on uni- and multivariable analyses, all studied elements
were not significant risk factors for SSI in the ERAS group. The
clinical impact of this finding might be that ERAS put all patients
(even patients with previously known risk factors such as male
gender and preoperative biliary stenting) at the same risk for SSI.
This could be explained by the fact that ERAS diminishes the
surgical stress response and improves the recovery by maintain-
ing the physiological homeostasis.[28] Early mobilization and
nutrition can also play a role in this change. It is also important to
mention that demographic characteristics and comorbidities of
the patients, such as gender, smoking, diabetes, and performance
status were not evenly distributed in both groups. This temporal
evolution could also be an explanation for the changes found in
risk factors for SSI. Moreover, the smaller number of patients in
the ERAS group might also have played a role in the results.
The nutritional status is a well-known risk factor for wound
problems in surgery in general.[22] Regarding pancreas surgery,
Kanda et al[29] showed that the nutritional status was associated
with survival and postoperative complications. In the ERAS
group, the nutritional status was not associated with SSI. In the
present ERAS cohort, patients with cancer and malnourished
patients (NRS >3) received preoperative supplemental nutrition
for 7 days, which could explain the fact that the nutritional status
was not correlated with SSI.
A high level of compliance to the ERAS pathwaywas associated
with less SSI than a low compliance level. Moreover, median
overall compliances were similar between the SSI group and the
group without SSI, suggesting that occurrence of SSI does not
impair the ERAS compliance. This highlights the importance of
applying all ERAS items, and that it is not a single element that is
more important than another, but really the powerful association
of all of them. A low compliance to ERAS pathways has already
been shown to be related to higher postoperative complication
rates, especially in colorectal surgery,[30,31] but also in pancreatic
surgery.[28] Based on this finding, it is therefore important to try to
achieve the best possible compliance for every single patient in
order to improve the postoperative outcomes. In addition, the fact
that ERAS and non-ERAS patients had in this cohort similar
postoperative complications and LoS can be partly explained by a
decline in compliance to the ERAS pathway in 2015 (data not
shown). This decrease in compliance can be an explanation for the
absence of complication andLoSdifference compared to the recent
published literature on ERAS in pancreas surgery.
LoS was prolonged for patients with SSI compared to patients
without SSI. As SSI is one of the most common complications
after pancreas surgery,[4] it impacts considerably on hospital
costs.[32] Prevention of SSI should therefore be undertaken to
improve patient recovery and to reduce hospital stay and its
related additional costs.[32]5
This study has several limitations that need to be mentioned.
This was a retrospective study inducing possible collection biases.
Moreover, this study covered a 15-year period where treatment
trends have changed. Of note, patients operated between 2000
and 2009 had similar pre-, intra-, and postoperative data as
patients operated between 2010 and 2015. Risk factors in the
ERAS group could also have been influenced by a temporal trend,
and not only by implementation of an ERAS pathway. The
number of patients in the ERAS group (twice less as the pre-ERAS
cohort) could also have influenced the risk factor analysis,
considering the number of variables included in the multivariable
analysis. Finally, nutritional status (NRS) was not available for
the non-ERAS group precluding a comparison between non-
ERAS and ERAS patients. Despite these limitations, this article is
original as it is one of the first studies assessing risk factors for SSI
within an ERAS protocol for pancreas surgery.
In conclusion, preoperative biliary stenting and male gender
were the most relevant risk factors to develop SSI after pancreas
surgery in a non-ERAS cohort. In the ERAS group, no significant
perioperative risk factors for SSI were found. Moreover, in the
present cohort of ERAS patients, obtaining a high overall ERAS
pathway compliance rate was associated with a lower SSI rate.Acknowledgments
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[31] Pędziwiatr M, Kisialeuski M, Wierdak M, et al. Early implementation of
Enhanced Recovery After Surgery (ERAS) protocol–compliance
improves outcomes: a prospective cohort study. Int J Surg 2015;21:
75–81.
[32] Ceppa EP, Pitt HA, House MG, et al. Reducing surgical site infections in
hepatopancreatobiliary surgery. HPB 2013;15:384–91.
